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ABSTRACT There is growing evidence that the com-
plement activation product C5a positively or negatively
regulates inflammatory functions. The studies pre-
sented here report that C5a exerts anti-inflammatory
effects by altering production of the cytokines IL-17A
and IL-23 during endotoxic shock in young adult male
C57BL/6J mice and has similar effects on macrophages
from the same mice. IL-17A and IL-23 both appeared in
plasma during endotoxemia, and their neutralization
improved survival. The relevant sources of IL-17A
during endotoxemia were not CD4 cells,  T cells, or
NK cells but CD11bF4/80 macrophages. The addi-
tion in vitro of C5a to lipopolysaccharide-activated
peritoneal macrophages dose dependently antagonized
the production of IL-17A (IC50, 50–100 nM C5a) and
IL-23 (IC50, 10 nM C5a). This suppression required the
receptor C5aR, but was independent of the second C5a
receptor, C5L2. Genetic absence of C5aR was associ-
ated with much higher levels of IL-17A and IL-23 during
endotoxic shock. Mechanistically, C5a mediated its
effects on the IL-17A/IL-23 axis in a 2-step process.
C5a caused activation of the PI3K-Akt and MEK1/2-
ERK1/2 pathways, resulting in induction of IL-10,
which powerfully inhibited production of IL-17A and
IL-23. These data identify previously unknown mecha-
nisms by which the anaphylatoxin C5a limits acute
inflammation and antagonizes the IL-17A/IL-23 axis.—
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The complement system is a first line of innate
immune defenses, guarding the extracellular compart-
ments, eliminating microbes, and contributing substan-
tially to homeostasis (1, 2). The complement activation
product C3b has an essential role as an opsonic factor
that promotes phagocytosis, while complement anaphy-
latoxin C5a has been shown to display powerful biolog-
ical activities, including recruitment and activation of
phagocytes (3). C5a and its conversion product
C5adesArg bind with high affinity to C5a receptors C5aR
and C5L2, which are expressed abundantly on both
myeloid and nonmyeloid cells (4, 5). The C5aR recep-
tor belongs to the family of 7-transmembrane-spanning
and G-protein-coupled receptors (6, 7). C5L2 repre-
sents a second C5a receptor that was first described as
a “decoy receptor” due to the lack of Ca2 signaling
activity after receptor ligation with C5a or C5adesArg,
and perhaps C3adesArg. However, engagement of the
C5L2 receptor has recently been shown to activate
some signaling pathways, although such conclusions
are a matter of contention (8–10). Overall, C5a, via
C5aR and possibly C5L2, promotes inflammation, in-
cluding directing the influx and activation of polymor-
phonuclear neutrophils. Blockade of C5a or genetic
absence of its receptors affected neutrophil functions
and reduced acute systemic inflammation and medi-
ator production (11, 12). On the other hand, high
levels of C5a can also compromise innate immune
functions (13).
IL-17A is essential for host defense against extracel-
lular pathogens, such as Escherichia coli, Staphylococcus
aureus, and Candida spp., but also for the intracellular
pathogen, Mycobacterium tuberculosis (14). IL-17A pre-
dominantly interacts with nonleukocytic cells, such as
epithelial cells, fibroblasts, and endothelial cells, but
also with macrophages (15). From these cells, IL-17A
initiates production of other proinflammatory media-
tors, such as IL-1, TNF-, IL-6, and IL-8, as well as
G-CSF, collectively resulting in an influx of neutrophils
(15–17).
It is widely accepted that IL-17 and Th17 cells con-
tribute to the pathogenesis of autoimmune diseases,
based on findings in experimental models, such as
autoimmune encephalomyelitis and collagen-induced
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arthritis (18, 19). Commitment of naive T cells to the
Th17 lineage has been demonstrated to be induced by
a combination of the cytokines TGF and IL-6 (20, 21),
activating the transcription factor retinoid-related or-
phan receptor t (RORt; ref. 22). Later stages of Th17
cell differentiation (including clonal expansion, phe-
notype stabilization, and IL-17 production) also de-
pend on IL-23 (p40/p19) expression (18, 19). How-
ever, under certain circumstances, IL-17A can also be
produced independently of IL-23 (23). Despite the fact
that much attention has been given to CD4 T-helper
cells (Th17) as the origin of IL-17A, it is now
clear that during acute inflammatory responses, signif-
icant amounts of IL-17A may be derived from cells of
the innate immune system (16). Release of IL-17A has
been demonstrated from neutrophils, lymphocyte-tis-
sue inducer cells, iNKT cells,  T cells, and paneth
cells (16, 24). We have previously reported that deple-
tion of  T cells reduces IL-17A and improves survival
in the setting of polymicrobial sepsis, accompanied by
substantial suppression of the cytokine storm (25).
Production of IL-17A and IL-17F by cells of the macro-
phage lineage has also been described (26, 27), but so
far, the evidence that macrophages contribute to IL-
17A is limited.
In this report, we describe the ability of C5a to
negatively regulate the IL-17A/IL-23 axis after endo-
toxic shock and in macrophages after lipopolysaccha-
ride (LPS)-mediated activation of TLR4. Interestingly,
we find the effects of C5a to be related to phosphati-
dylinositol 3-kinase (PI3K)-Akt and MAPK/extracellular
signal-regulated kinase (ERK) kinase 1/2 (MEK1/2)–
ERK1/2-mediated induction of IL-10 from macrophages,
with IL-10 subsequently suppressing the IL-17A/IL-23
axis. Thus, C5a can exert predominantly anti-inflamma-
tory properties under some circumstances.
MATERIALS AND METHODS
Animals
All procedures were performed in accordance with the U.S.
National Institutes of Health guidelines and the University of
Michigan Committee on Use and Care of Animals. Male mice
of the strains C57BL/6J, IL-10/,  T cell/,  T
cell/, CD4 T cell/, myeloid differentiation primary
response gene 88 (MyD88)/, and Rorc(gt)gfp were pur-
chased from the Jackson Laboratories (Bar Harbor, ME,
USA). Male mice of the strains C5aR/ and C5L2/ were
bred at the University of Michigan. All animals were housed
under specific pathogen-free conditions.
Endotoxemia
The mice were injected with LPS i.p. (E. coli 0111:B4; Sigma-
Aldrich, St. Louis, MO, USA). Body weight of each individual
animal was measured directly before injection. Plasma was
collected using EDTA (5 mM) as an anticoagulant. For
survival studies, animals were monitored at least every 12 h for
8 d after challenge with LPS.
Isolation and incubation of macrophages
For elicitation of peritoneal-elicited macrophages (PEMs),
mice received 1.5 ml thioglycollate 2.4% i.p. (Becton Dickin-
son, Franklin Lakes, NJ, USA) or casein sodium salt 9%
(Sigma-Aldrich). PEMs were harvested 4 d later by peritoneal
lavage. After centrifugation, cells were resuspended in RPMI
1640 [25 mM HEPES, 100 U/ml penicillin-streptomycin (Life
Technologies), and 0.1% BSA (Sigma-Aldrich)], plated at 2 
106 cells/ml and incubated at 37°C, 5% CO2.
For bone marrow-derived macrophages (BMDMs), the
long bones were flushed with HBSS. Cells were cultured in
RPMI 1640 (25 mM HEPES, 100 U/ml penicillin-streptomy-
cin, 20% FCS, and 30% L-cell conditioned medium), supple-
mented with fresh medium after 3 d and incubated for a total
of 7 d.
For isolation of alveolar macrophages, the lungs were
removed and lavaged 20 with 1 ml PBS (0.5 mM EDTA).
The MH-S cell line was a gift from Dr. J. Weinberg (University
of Michigan).
At the end of all experiments, supernatants were cleared of
nonadherent cells by centrifugation and stored at 80°C
until further analysis. For light microscopic phenotyping of
macrophage preparations, cytospins were stained with a mod-
ified Wright-Giemsa method (Hema 3 Stain Set; Fisher Sci-
entific, Pittsburgh, PA, USA).
Measurement of mediator concentrations by ELISA and
Luminex
The following mouse ELISA kits were used: IL-17A, TNF-,
IL-23(p19), IL-10 (all from R&D Systems, Minneapolis, MN,
USA). ELISAs were performed according to the instructions
of the manufacturer. The mouse C5a ELISA was performed
with reagents from BD Biosciences (San Jose, CA, USA), as
described earlier (28). For simultaneous measuring of 23
mouse cytokines, a bead-based assay was used (Luminex and
BioPlex 200; Bio-Rad, Hercules, CA, USA). Processing of
samples and data analysis was performed according to man-
ufacturer’s instructions as described before (29).
Isolation of mRNA and real-time PCR
Total RNA was obtained from macrophages by the TRIzol
method. The cDNA was generated with TaqMan Reverse Tran-
scription Reagents (Applied Biosystems, Carlsbad, CA, USA).
Amplification was performed with SYBR Green Mastermix in the
7500 real-time PCR system (Applied Biosystems). Results were
analyzed by the 2Ct relative quantification method and
normalized to GAPDH. Primer sequences were as follows:
mouse IL-17A, forward 5	-CTCCAGAAGGCCCTCAGACTAC-3	
and reverse 5	-AGCTTTCCCTCCGCATTGACACAG-3	; mouse
RORt, forward 5	-CCGCTGAGAGGGCTTCAC-3	 and reverse
5	-TGCAGGAGTAGGCCACATTACA-3	; mouse GAPDH, forward
5	-TACCCCCAATGTGTCCGTCGTG-3	 and reverse 5	-CCTTCA-
GTGGGCCCTCAGATGC-3	 (all from Invitrogen, Carlsbad,
CA, USA).
Flow cytometry
After incubation with Brefeldin A, cells were processed using
the Cytofix/Cytoperm Plus Fixation/Permeabilization Kit
(BD Biosciences) and BD Fc Block. For detection of phos-
phoproteins, cells were fixed and permeabilized with Perm
Buffer III (BD Biosciences). A minimum of 50,000 events
were acquired on a BD LSR II flow cytometer (BD Biosci-
ences). All antibodies used were anti-mouse together with
matched fluorochrome-labeled isotype controls. From BD
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Pharmingen: AF488 IL-17A (clone TC11-18H10), PE  T-cell
receptor (clone GL3), PE Akt(pT308) (clone J1-223.371),
and PE ERK1/2(pT202/pY204) (clone 20A). From eBiosci-
ence (San Diego, CA, USA): APC F4/80 (clone BM8), AF 700
CD11b (clone M1/70), PE CD11c (clone N418), PE CD4
(clone RM4–5), and PerCP-Cy5.5 CD3e (clone 145-2C11).
From R&D Systems: PE CCR6 (clone 140706).
Microscopy
Spleens were snap-frozen, cryosectioned, and fixed with 4%
formaldehyde solution (Thermo Scientific, Pittsburgh, PA,
USA). After blocking with 7% BSA, 10% normal mouse
serum, and endogenous biotin (blocking kit; Invitrogen), the
sections were incubated overnight with primary antibodies,
1 h with secondary antibodies, and mounted with prolong
gold/DAPI (Invitrogen). Antibodies used were goat anti-
mouse IL-17A (R&D Systems), rat anti-mouse F4/80 (eBiosci-
ence), rabbit anti-goat biotinylated IgG, streptavidin AF488,
and rabbit anti-rat AF594 (all from Invitrogen). Confocal
images were acquired with a Zeiss LSM 510-META laser
scanning confocal microscope ( 40/1.2 W, 63/1.2 W; Carl
Zeiss, Oberkochen, Germany) with LSM 510 software. Light
microscopic images of cytospins were acquired using an
Olympus BX-51 microscope (40/0.9, 60/1.4 oil, 100/
1.4 oil) with an Olympus DP-70 high-resolution digital camera
and DP controller software (Olympus, Tokyo, Japan).
Antibodies and reagents
TLR agonists were obtained from Invivogen (San Diego, CA,
USA): TLR2 (zymosan, Saccharomyces cerevisiae), TLR3 (poly
I:C), TLR5 (flagellin, Bacillus subtilis), and TLR9 (type A CpG
oligonucleotide ODN1518 and ODN1585 control). LPS (E.
coli, 0111:B4) and N-formyl-Met-Leu-Phe (fMLP) were ob-
tained from Sigma-Aldrich; LY294002, PD98059, and U0126
were obtained from Invivogen.
Neutralizing goat anti-mouse IL-23(p19) IgG, total goat IgG,
rmC5a, rmIL-10, and rmIL-23 were obtained from R&D
Systems; neutralizing anti-mouse IL-17A and control antibody
from eBioscience; anti-asialo GM1 rabbit NK cell-depleting
antiserum and normal rabbit serum from Wako Pure Chem-
icals (Richmond, VA, USA); rmIL-6 and rhTGF1 from
PeproTech (Rocky Hill, NJ, USA); rat IgG2B isotype control
antibody from BioLegend (San Diego, CA, USA). The neu-
tralizing anti-F4/80 antibody was generated from clone HB-
198 (American Type Culture Collection, Manassas, VA, USA)
and used as described before by others (30, 31).
Statistical analysis
GraphPad Prism 5.01 software (GraphPad, San Diego, CA,
USA) was used for figure preparation and statistical analysis.
All values are expressed as means, and error bars represent
means 
 se. Data sets were analyzed by 1-way ANOVA and
Student’s t test and survival curves by log-rank (Mantel-Cox)
test. In vivo experiments were done with numbers of animals
per group as indicated in the figure legends (n3). In vitro
experiments were independently performed 3 times, and
representative experiments are shown. We considered differ-
ences significant at values of P  0.05.
RESULTS
Blocking of IL-17A or IL-23(p19) improves survival
after endotoxic shock
To investigate the role of IL-17A and IL-23(p19) during
acute systemic inflammation, we challenged C57BL/6J
mice with LPS [10 mg/kg body weight (BW) i.p.], a
dose causing 60–80% lethality. Plasma collected from
these mice at several time points showed an early,
transient surge of IL-23(p19), peaking in 3 h, with levels
of 800 pg/ml (Fig. 1A). The same samples revealed a
12 h peak for IL-17A (Fig. 1B), although IL-17A was
already elevated over baseline levels by 3 h. Conse-
quently, in all further experiments for detection of
plasma IL-17A, a time point of 12 h was used unless
otherwise indicated. Next, we pretreated C57BL/6J
mice with a neutralizing polyclonal anti-IL-23 antise-
rum, specific for the p19 subunit of IL-23(p19/p40).
Blockade of IL-23(p19) resulted in a significantly im-
proved survival after challenge with LPS (Fig. 1C).
Similarly, neutralization of IL-17A was also potently
protective during endotoxemia and increased survival
from 40 to 100% when anti-IL-17A was given immedi-
ately before LPS (Fig. 1D). Together, this indicated that
the IL-17A/IL-23 axis drives lethal systemic inflamma-
tion in the endotoxemia model. To elucidate the
cellular source of IL-17A release during endotoxemia,
we compared C57BL/6J mice to mice genetically defi-
cient of CD4 or  T cells. Unexpectedly, the absence
of CD4 or  T cells did not significantly affect levels of
plasma IL-17A during endotoxic shock (Fig. 1E, F).
IL-17A levels were also not reduced when NK cells were
depleted before endotoxemia (Fig. 1G). However, pre-
treatment with a monoclonal antibody directed against
the surface marker F4/80 for depletion of macro-
phages resulted in markedly diminished circulating
IL-17A levels after endotoxic shock compared to mice
treated with isotype control antibody (Fig. 1H). This
anti-F4/80 antibody has been demonstrated before by
others to effectively deplete F4/80 macrophages (30,
31). Additional evidence that F4/80 macrophages are
a source of IL-17A in vivo was acquired by confocal
microscopy. Sections of spleens from endotoxemic
wild-type (Wt) mice were stained for F4/80, as well as
for intracellular IL-17A and showed colocalization of
IL-17A in F4/80 cells in the spleen (Fig. 1I, bottom
panel). Only a few IL-17AF4/80 cells were seen in
spleens of endotoxemic mice, which may be due to
rapid secretion of IL-17A. Sections from untreated
healthy mice as controls displayed little detectable
fluorescent intensity for IL-17A, whereas F4/80 mac-
rophages were also present in the spleens of these sham
mice (Fig. 1I, top panel). No other cell type except
F4/80 macrophages stained consistently positive for
IL-17A in the spleen of endotoxemic mice, when com-
pared to staining with isotype controls (data not
shown). Overall, the levels of IL-17A after endotoxemia
appear to be generated at least to some extent by cells
of the monocyte/macrophage lineage.
Release of IL-17A by macrophages after TLR4
activation
To further investigate the possibility of macrophages
being a source of IL-17A, mouse peritoneal and alveo-
lar macrophages were assessed in vitro. Peritoneal cells
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isolated from C57BL/6J mice 4 d after intraperitoneal
injection of thioglycollate were found to be 85–90%
macrophages with extensive vacuole presence, based
on light microscopic differential cell count (Fig. 2A)
and expression of F4/80 and CD11b surface markers
(Supplemental Table S1A, C). Macrophages were incu-
bated for 10 h using a dose range of LPS (10 g/ml to
10 ng/ml), and levels of IL-17A released into cell
supernatant fluids were measured by ELISA (Fig. 2B).
LPS concentrations 50 ng/ml induced a highly ro-
bust production of IL-17A. For further experiments,
LPS at a concentration of 1 g/ml was employed.
Figure 2C shows the time course for release of IL-17A
from LPS-stimulated macrophages, with a peak in IL-
17A levels after 12 h, which is superimposable with the
IL-17A kinetics described after endotoxemia (Fig. 1B).
Comparable levels of LPS-induced IL-17A were detect-
able when casein, an alternative to thioglycollate, was
used to elicit peritoneal macrophages (Fig. 2D). To
determine the capability of mouse alveolar macro-
phages to produce IL-17A, these cells were harvested by
lavage of the airways of normal C57BL/6J mice fol-
lowed by in vitro cultivation. Cells from such BAL fluids
were 98% macrophages, as determined by light mi-
croscopy (Fig. 2E). These alveolar macrophages re-
leased IL-17A after stimulation with LPS (Fig. 2F). The
alveolar macrophage cell line, MH-S, also released
IL-17A after LPS (Fig. 2G).
BMDMs were also studied for IL-17A production. In
supernatant fluids from LPS-stimulated BMDMs, IL-
17A was not detectable (15 pg/ml), despite abundant
production of TNF- (Fig. 2H). The polarization of
BMDMs to the classic M1 phenotype after 24 h incuba-
tion with interferon- alone or in combination with
low-dose LPS did not result in IL-17A production (data
not shown).
Characterization for surface markers and mediator
production by PEMs and BMDMs after TLR4 activation
are summarized in Supplemental Table S1. PEMs and
BMDMs showed abundant F4/80 (86 vs. 98%, respec-
Figure 1. Neutralizing of IL-17A or IL-23(p19)
improves survival after endotoxemia. A)
Time course of IL-23(p19) in plasma after LPS
challenge of C57BL/6J mice in vivo (n5/
group), ELISA. B) Time course of IL-17A in
plasma after LPS challenge in vivo (n5/
group). C) Survival of C57BL/6J mice in
endotoxemia with pretreatment of neutraliz-
ing IL-23(p19) (n9) antibody or control
antibody (n12), 20 g antibody/animal
i.p., LPS 12.5 mg/kg BW i.p. D) Survival of C57BL/6J mice in endotoxemia pretreated with neutralizing IL-17A
antibody (n9) or control antibody (n10), 70 g antibody/animal i.p. E) Plasma levels of IL-17A of endotoxemic
CD4/ mice (n4) compared to C57BL/6J mice (n5) as control, 12 h. F) Plasma levels of IL-17A in endotoxemia
in TCR/ mice (n5) and C57BL/6J mice (n8) as control, 12 h. G) Plasma levels of IL-17A 12 h after
endotoxemia with depletion of NK cells by anti-asialo GM antiserum (50 l/mouse i.p. on d 1) or control serum
(n9/group). H) Reduction of IL-17A plasma levels 12 h after endotoxemia after pretreatment with an anti-F4/80
macrophage-depleting antibody or IgG2B isotype control antibody (n5; 500 g i.p. on d 3 and 1). I) Confocal
microscopy of spleen sections from sham-treated mice or mice 3 h after endotoxemia. Stainings for IL-17A (AF488,
green), F4/80 (AF594, red), and merged images are shown. Scale bars  15 m). Dose of LPS was 10 mg/kg BW i.p.
for all experiments except C. Error bars represent means 
 se. n.s., not significant. *P  0.05, ***P  0.001; Student’s
t test.
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tively) and CD11b (87 vs. 98%, respectively) expres-
sion and were typically F4/80CD11b double-positive.
These cells displayed low expression profiles for CD11c
(15%). There was a trend for PEMs to release higher
quantities of IL-23(p19) compared to BMDMs. PEMs and
BMDMs both displayed a TNF-high, IL-1high, IL-12high,
IL-10low phenotype, consistent with an M1 classic polar-
ization (Supplemental Table S1B). This suggests that
macrophages that express mediators of the M1 pheno-
type (as in PEMs and alveolar macrophages) may or
may not (as in BMDMs) express IL-17A.
By RT-PCR, there was no measurable RORt mRNA
expression detectable after activation of macrophages
with LPS (data not shown). In addition, there were no
signs of the presence of RORt in LPS-stimulated
macrophages from RORteGFP transgenic mice (Sup-
plemental Fig. S1). Collectively, these data suggest that,
under the conditions employed, there was no evidence
of activation of RORt, which is consistent with a recent
report using macrophages (26).
TLR4 activation induces IL-17A expression in
F4/80CD11b macrophages
The PEM preparations contained small numbers of
nonmacrophage cells, namely CD3 cells (Supplemen-
tal Table S1C). To further investigate the nature of the
IL-17A-producing cells after TLR4 activation, we used
flow cytometry analysis. Costaining for intracellular
IL-17A in combination with the presence of surface
markers employing anti-CD11b and anti-F4/80 showed
a distinct population of double-positive PEMs, consis-
tent with IL-17A cells being macrophages (Fig. 3A).
Macrophages displayed a CD11bF4/80 phenotype.
Despite small contamination of PEM preparations with
CD3 cells, there was virtually no staining (0.4%) for
IL-17A in CD3 CD4 cells (Supplemental Table S1C).
We previously reported that  T cells are required
for the appearance in plasma of IL-17A after cecal
ligation and puncture (25). In PEM preparations,  T
cells were virtually undetectable (Supplemental Table
S1C). To further evaluate a role of , T cells for
maturation of macrophages into an IL-17A-producing
phenotype, we studied PEMs from  TCR/ mice.
After elicitation of macrophages with thioglycollate,
PEMs from  TCR/ mice displayed, if anything,
slightly higher levels of IL-17A compared to Wt cells
(Fig. 3B). Similar results were obtained with PEMs from
 T-cell/ mice that contain no CD4, CD8 or
CD4CD8 cells (Fig. 3C), which should be associated
with the absence of Th17 differentiated cells. These
results suggest that the release of IL-17A by PEMs or
alveolar macrophages is independent of  T cells and
 T cells. Unlike for Th17 cells, in macrophages, IL-6
and TGF did not promote IL-17A production (Sup-
plemental Fig. S2).
Release of IL-17A after TLR4 activation is MyD88
dependent
We sought to examine whether expression of IL-17A by
macrophages could be induced by TLRs other than
TLR4. Therefore, we stimulated PEMs with zymosan
(TLR2), poly I:C (TLR3), LPS (TLR4), flagellin (TLR5),
Figure 2. IL-17A release by macrophages from different origins. A) PEMs from C57BL/6J (Wt) mice were isolated from the
peritoneum after elicitation with thioglycollate and stained after Wright-Giemsa. B) Production of IL-17A by PEMs incubated for
10 h at 37°C with a dose range of LPS (0.01–10 g/ml), ELISA. C) Time course for IL-17A production from PEMs incubated
with LPS (1 g/ml) for 3–24 h. D) IL-17A release by thioglycollate- or casein-elicited PEMs after incubation with LPS (1 g/ml)
for 10 h. E) Alveolar macrophages harvested from BAL fluids of untreated C57BL/6J mice and stained after Wright-Giemsa.
F) IL-17A release by alveolar macrophages after incubation with LPS (1 g/ml) for 10 h. G) Production of IL-17A by MH-S cells
(SV40 transformed alveolar macrophage cell line), 10 h. H) Absence of detectable IL-17A release in LPS-stimulated BMDMs
from C57BL/6J mice despite abundant production of TNF- after 10 h. Control (Ctrl) denotes untreated macrophages cultured
in medium alone. Error bars represent means 
 se. *P  0.05, **P  0.01, ***P  0.001; Student’s t test.
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and CpG (TLR9) for 12 h. Only TLR4 activation by LPS
resulted in robust accumulation of IL-17A in the cell
culture supernatants (Fig. 3D).
The recognition of LPS by the TLR4 receptor on
macrophages is known to initiate recruitment of the
adaptor protein MyD88 to the ligand-receptor com-
plex, although some responses after TLR4 activation
are independent of MyD88 but dependent on TRIF. To
investigate the role of MyD88 for IL-17A production
from LPS-activated macrophages, we compared cells
from C57BL/6J mice (Wt) with macrophage prepara-
tions from MyD88/ mice. As shown in Fig. 3E,
macrophages devoid of MyD88 produced very little
IL-17A in response to LPS (1 g/ml). In unstimulated
Wt macrophages, mRNA levels for IL-17A were barely
detectable. After activation of the TLR4 pathway by
LPS, there was a steep increase of mRNA content for
IL-17A in Wt macrophages but not in MyD88/
macrophages (Fig. 3F). Similar results for IL-23(p19)
were obtained, and they indicated that the release of
IL-23(p19) from PEMs is also dependent on MyD88
(data not shown).
C5a suppresses IL-17A and IL-23(p19) release from
macrophages
Complement activation results in the enzymatic cleav-
age of C5 and appearance of the 74–78 aa peptide
(depending on species), potent anaphylatoxin, C5a. In
macrophages incubated with LPS in the copresence of
recombinant C5a, there was a dose-dependent reduc-
tion of IL-17A release with an IC50 of 50–100 nM C5a
(Fig. 4A). This suppressive activity was specific for C5a,
since addition of fMLP, which is a chemotactic peptide
derived from bacteria and reactive with its G-protein-
coupled receptor, did not affect LPS-induced release of
IL-17A from PEMs (Fig. 4B). The appearance of IL-17A
in culture supernatant fluids (Fig. 4C) and the suppres-
sive effects of C5a were also reflected by changes in
mRNA levels for IL-17A. After incubation with LPS, the
relative mRNA expression levels for IL-17A were in-
creased as early as 3 h and preceded the appearance of
IL-17A in cell culture medium, and C5a was inhibitory
at all the time points studied (Fig. 4D).
We assessed the relative contributions of the C5aR
and C5L2 receptors to C5a-mediated negative regula-
tion of IL-17A production. PEMs were obtained from
Wt, C5aR/, and C5L2/ mice, and cells were stim-
ulated with either LPS or the combination of LPS (1
g/ml) and C5a (100 nM). Relative changes due to the
copresence of C5a were expressed as percentage values
of IL-17A levels (Fig. 4E). The copresence of 100 nM
C5a with LPS, when added to Wt macrophages, resulted
in 55% inhibition in IL-17A production. C5a was
unable to suppress IL-17A release in PEMs lacking
C5aR. However, inhibition by C5a was fully expressed
in PEMs deficient in the C5L2 receptor, suggesting that
C5L2 is dispensable for mediating C5a-related inhibi-
tion of IL-17A, but not C5aR. Furthermore, macro-
phages from C5aR/ mice displayed enhanced con-
centrations of IL-17A after LPS incubation when
compared to cells from Wt mice (Fig. 4F). Taken
together, these data indicate that C5a-induced suppres-
sion of IL-17A in LPS-stimulated PEMs requires engage-
ment of C5aR.
Regarding IL-23 production in macrophages, we found
that PEMs abundantly released IL-23(p19) within 10 h after
TLR4 activation but not with TLR2, TLR3, TLR5, or
TLR9 agonists (Supplemental Fig. S3). Interestingly, C5a,
in a dose-dependent manner, inhibited IL-23(p19) release
from PEMs, with an IC50 of 10 nM (Fig. 4G). This
suppressive effect also required the presence of C5aR
Figure 3. Characterization of IL-17A release by mac-
rophages. A) Flow cytometry analysis for intracellular
cytokine staining for IL-17A as a function of the
macrophage surface markers, CD11b and F4/80.
B) IL-17A release from LPS-activated PEMs from
C57BL/6J mice compared to cells from  T-cell-
deficient mice. C) Release of IL-17A from PEMs from
 T-cell-deficient mice after LPS activation. D) Re-
lease of IL-17A from Wt macrophages after stimulation
with agonists for TLR2, TLR3, TLR4, TLR5, and TLR9 (all at 1 g/ml). E) Release of IL-17A from LPS-activated PEMs from
C57BL/6J mice and MyD88/ mice. F) RT-PCR analysis of mRNA levels for IL-17A in LPS-stimulated PEMs from
C57BL/6J mice and MyD88/ mice. Control (Ctrl) denotes untreated PEMs in cell culture medium alone. LPS (1 g/ml)
and 12 h incubation for all experiments. Error bars represent means 
 se. **P  0.01, ***P  0.001; Student’s t test.
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(Fig. 4H). Absence of the C5L2 receptor did not affect the
ability of C5a to inhibit IL-23 expression.
C5a via C5aR regulates the IL-17A/IL-23 axis during
endotoxic shock
Complement activation occurs during murine endotox-
emia, as indicated by an increase of levels for C5a in
plasma of endotoxemic C57BL/6J (Wt) mice (Fig. 5A).
We have recently described that the peak of such C5a
levels is observed after 6 h (28). Given the data pre-
sented above, that suppression of the IL-17A/IL-23 axis by
C5a requires the C5aR receptor, we decided to study
mediator production in C5aR/ mice during endotoxic
shock. Analysis of IL-23(p19) revealed that in C5aR
/
mice circulating plasma levels were 3-fold higher as com-
pared to Wt mice after 12 h (Fig. 5B). In the same
samples, the levels of IL-17A in the group of mice with
genetic deficiency of C5aR averaged 2000 pg/ml, which
was 6-fold higher than the levels in the Wt group (Fig.
5C). Interestingly, at the same time, plasma from
C5aR/ mice after endotoxemia had reduced levels of
the anti-inflammatory cytokine IL-10 (Fig. 5D).
C5a inhibits the IL-17A/IL-23 axis via IL-10
Because C5aR/ mice displayed lower levels of circu-
lating plasma IL-10 after in vivo challenge with LPS
Figure 4. Ability of C5a to suppress
IL-17A production in macrophages.
A) PEMs (Wt) were incubated with
LPS (1 g/ml) in the copresence of
the indicated concentrations of re-
combinant mouse C5a. Concentra-
tions of IL-17A (ELISA) were de-
tected in cell culture supernatants
after 10 h. B) IL-17A release of PEMs
after 10 h incubation with LPS alone
or in combination with the bacterial
chemotactic peptide, N-formyl-Met-
Leu-Phe (fMLP). C) Time course for
IL-17A release after stimulation with
LPS or LPS plus C5a. D) Quantitative
RT-PCR analysis of IL-17A mRNA expression at different time points after stimulation with LPS or LPS plus C5a
(100 nM). E) Relative inhibition of LPS-induced IL-17A release by C5a (100 nM) in macrophages obtained from
C57BL/6J, C5aR/, and C5L2/ mice. Macrophages from the 3 mouse strains were isolated and stimulated
in parallel with LPS or LPS plus C5a for 10 h. Data are expressed in percentage values, in which the IL-17A
concentration with LPS alone for each animal strain and experiment was used as 100%. F) Comparison of IL-17A
concentrations released from C57BL/6J and C5aR/ macrophages. G) Release of IL-23(p19) after stimulation
with LPS alone or together with different concentrations of C5a. H) Relative inhibition of IL-23(p19) release
mediated by C5a from LPS-stimulated macrophages. Cells from C57BL/6J, C5aR/, and C5L2/ mice were
stimulated in parallel with LPS in the presence or absence of C5a. IL-23(p19) release after LPS alone was used
as the 100% value for each individual mouse strain. Error bars represent means 
 se. n.s., not significant. *P 
0.05, **P  0.01, ***P  0.001; Student’s t test.
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(Fig. 5D), we expanded our in vitro studies to the effects
of C5a on IL-10, including a suggested relevance to the
IL-17A/IL-23 axis. We assessed release of IL-10 from
PEMs stimulated with LPS in the absence or copresence
of recombinant mouse C5a (Fig. 6A). There was a
3–5-fold enhancement of IL-10 levels by C5a (100 nM)
in the copresence of LPS. Notably, C5a in the absence
of LPS did not induce IL-10 release. IL-10 was present
in macrophage supernatant fluids already at early time
points after addition of C5a and LPS, preceding the
release of IL-17A (Fig. 6B). C5a was ineffective in
altering IL-10 levels in C5aR/ PEMs, but IL-10 was
robustly enhanced in C5L2/ PEMs (Fig. 6C).
To investigate whether the enhancement of IL-10 by
C5a relates to its ability to suppress IL-17A and IL-
23(p19) release, we coincubated macrophages with re-
combinant IL-10 during TLR4 activation (Fig. 6D, E).
The addition of IL-10-mediated potent suppression of
the release of IL-17A and IL-23(p19), with an IC50 of
100 pg/ml. With IL-10 concentrations 1 ng/ml,
production of IL-17A and IL-23(p19) was completely
suppressed. Macrophages from IL-10/ mice were
stimulated with LPS, in parallel with Wt macrophages.
Using IL-10/ macrophages, we found that copres-
ence of C5a with LPS reduced inhibition when com-
pared to Wt macrophages (17 vs. 48%) of IL-17A
release (Fig. 6F). In addition, the IL-10/ macro-
phages displayed 10-fold elevated levels of IL-17A
after LPS (Fig. 6F). Using RT-PCR, we assessed the
suppression of IL-17A by IL-10 on the mRNA level. The
addition of IL-10 to LPS-activated PEMs markedly re-
duced the message levels for IL-17A (Fig. 6G). The in
vivo relevance of IL-10 for controlling the release of
IL-17A and IL-23(p19) was demonstrated by the fact that
IL-10/ mice showed dramatically elevated levels of
both mediators during endotoxemia (Fig. 6H, I). In the
genetic absence of IL-10, the rise of plasma levels of
IL-17A was 28-fold higher, and the plasma levels of
IL-23(p19) were 15-fold higher, as compared to Wt mice.
It is well known that IL-10/ mice are hypersuscepti-
ble to endotoxic shock, and this is consistent with our
own findings (data not shown). In summary, we found
a robust and profound suppression of the IL-17A/IL-23
axis by IL-10, whose presence was markedly enhanced
by the complement activation product C5a in macro-
phages, while C5aR/ mice had diminished IL-10
levels in endotoxemia (Fig. 5D).
C5a enhances IL-10 release by activation of PI3K-Akt
and MEK1/2-ERK1/2 pathways
To investigate intracellular signaling mechanisms by
which C5a enhances the release of IL-10 from LPS-
activated macrophages, we focused on the PI3K-Akt and
MEK1/2-ERK1/2 signaling pathways. We and others have
previously shown that C5a activates Akt and ERK1/2
pathways in neutrophils and macrophages (13, 28, 32).
Indeed, incubation of PEMs with recombinant C5a (100
nM) for 10 min showed a significant increase of phos-
phorylated Akt as detected by flow cytometry (Fig. 7A).
The antibody used was specific for phosphorylation of a
tyrosine amino acid residue at position 308 of Akt. The
stimulation with C5a also activated ERK1/2, as indicated
by increased phosphorylation at the amino acid residues
threonine 202 and tyrosine 204 (Fig. 7B). Next, the
potential of C5a to modulate activation of Akt in macro-
phages from Wt vs. C5aR/ mice was compared (Fig.
7C). A 20-min stimulation with LPS resulted in compara-
ble proportions of F4/80 macrophages being positive for
phosphorylated Akt (30.7% in Wt vs. 32.0% in C5aR/).
However, Akt activation in Wt macrophages was further
amplified with costimulation of LPS plus C5a (44.3% in
Wt vs. 32.5% in C5aR/). After incubation of Wt mac-
rophages and C5aR/ macrophages with LPS, 22.6%
and 20.0% of the cells were double positive for F4/80 and
phosphorylated ERK1/2, respectively (Fig. 7D). The ad-
dition of C5a together with LPS resulted in a 2-fold
increased population of F4/80p-ERK1/2 macrophages
(45.6%). This effect of C5a was not observed in C5aR/
macrophages (22.7%). In macrophages from Wt mice,
the C5aR receptor is abundantly expressed on F4/80
macrophages (data not shown), but in C5aR/ macro-
phages, C5a in the copresence of LPS failed to amplify Akt
and ERK1/2 phosphorylation. Taken together, the data
suggest that Akt and ERK1/2 activation by C5a both
required the presence of the C5aR receptor, similar to the
findings above, namely that C5aR is essential for C5a-
mediated induction of IL-10. When the activation of the
PI3K/Akt pathway was blocked with LY294002, a specific
Figure 5. Role of C5a and the C5aR receptor for mediator
production in endotoxic shock. A) Levels of C5a in plasma
from Wt mice 6 h after endotoxemia compared to untreated
healthy Wt mice (sham, n4/group), ELISA. B) Plasma levels
of circulating IL-23(p19) in C5aR
/ and Wt mice (n5/
group) during endotoxemia, 12 h, ELISA. C) Hyperproduc-
tion of IL-17A as detected in plasma of C5aR/ mice (n7)
and compared to Wt mice (n9) during endotoxic shock,
12 h. D) Plasma levels of circulating IL-10 during endotoxic
shock in C5aR/ and Wt mice (12 h, n5/group). LPS 7.5
mg/kg BW i.p. for all experiments. Error bars represent
means 
 se.*P  0.05, **P  0.01, ***P  0.001; Student’s t
test.
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inhibitor of PI3K, thus preventing phosphorylation of
downstream Akt, the production of IL-10 from PEMs was
substantially suppressed (Fig. 7E). Furthermore, pretreat-
ment with PD98059 or U0126, both selective inhibitors of
the MEK1/2 and ERK1/2 pathways, blocked IL-10 release
from macrophages (Fig. 7E, F). In conclusion, the PI3K-
Akt and MEK1/2-ERK1/2 are activated by C5a in F4/80
macrophages, and these pathways appear to be crucial for
the release of IL-10.
DISCUSSION
LPS is a highly reactive molecule able to induce acute
inflammation in murine models of disease, as well as in
humans, as established by the infusion of LPS into
human volunteers at the National Institutes of Health
several decades ago. The acute febrile response is
accompanied by a robust activation of the coagulation
cascades, accompanied by neutrophilia and the appear-
ance of proinflammatory cytokines and chemokines in
plasma (33, 34). In humans with sepsis, LPS has been
detected in patients with gram-negative sepsis and
occurs in patients with Klebsiella or Pseudomonas pneu-
monias, after penetrating abdominal injuries, and dur-
ing urosepsis. Here, we report evidence that IL-17A and
IL-23 play crucial roles after LPS-induced shock. IL-17A
is an essential mediator in immune responses, as well as
in innate immunity, and is produced not only by CD4
Th17 cells but by innate immune cells, such as  T
Figure 6. C5a suppresses the IL-17A/IL-23 axis via enhancement of IL-10. A) ELISA of IL-10 release after incubation with LPS (1
g/ml, 10 h) in PEMs from C57BL/6J mice in the absence or copresence of recombinant C5a or C5a alone. B) Time course of IL-10
production from PEMs stimulated with LPS 
 C5a. C) Enhancement of IL-10 production by C5a is signaled via C5aR but not C5L2.
Relative stimulatory effect of C5a plus LPS compared to LPS alone (100%) in C57BL/6J, C5aR/ and C5L2/ macrophages. D)
Effect of different concentrations of recombinant IL-10 on release of IL-17A after LPS, 10 h. E) Effect of recombinant IL-10 on release
of IL-23(p19) from LPS stimulated PEMs, 10 h. F) Reduced inhibition by C5a on IL-17A release in LPS-stimulated macrophages from
IL-10/ mice compared to Wt. Percentage numbers indicate the relative inhibitory effect of C5a. G) Quantitative RT-PCR analysis
of the effects of recombinant IL-10 on mRNA levels for IL-17A, 8 h. H) Plasma levels of IL-23(p19) during endotoxic shock in
C57BL/6J Wt mice (n9) and IL-10/ mice (n6), 10 h. I) Plasma levels of IL-17A during endotoxic shock in Wt mice (n9) and
IL-10/ mice (n6), 10 h. Error bars represent means 
 se. *P  0.05, ***P  0.001; Student’s t test.
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cells, neutrophils, paneth cells, etc. (16). In addition to
existing reports (26, 27), we provide further evidence
for the ability of PEMs to function as a source of IL-17A
after activation by LPS in a MyD88-dependent manner.
Such events may relate to the outcome of endotoxic
shock. Initially, we were concerned about the possibility
that PEM preparations might have been contaminated
with other IL-17A-producing cell populations, such as
Th17 or  T cells. However, flow cytometric studies
and depletion of macrophages with an anti-F4/80
antibody confirmed macrophages as a relevant source
of IL-17A. Alveolar macrophages also released IL-17A
after in vitro stimulation with LPS.
We found robust suppressive activities of the comple-
ment product C5a on the IL-17A/IL-23 axis in the
context of endotoxic shock and in LPS-activated PEMs.
The C5a-mediated inhibition of mediators required
relatively high concentrations of C5a (10–100 nM) in
vitro, but comparable levels are found in endotoxemia
(28). At higher concentrations, C5a appears to act in an
anti-inflammatory manner, which is underscored by its
ability to potently augment IL-10 release. We found a
clear functional divergence of the C5aR and C5L2
receptors, with only the C5aR receptor being required
for C5a to inhibit IL-17A and IL-23(p19). C5L2 was
completely dispensable for the suppressive effects of
C5a. Since the C5aR receptor is expressed on numer-
ous cell types, it cannot be excluded that cells other
than macrophages contribute directly or indirectly in
the alterations of IL-17A, IL-23, and IL-10 levels after
endotoxemia in C5aR/ mice. Noteworthy, C5aR/
mice have been reported to be protected in lethal
endotoxemia, E. coli bacteremia and CLP (12, 35).
Thus, it can be concluded that the suppressive effects of
C5a on the IL-17A/IL-23 axis and IL-10 in these models
are somewhat outbalanced by other biological effects of
C5a resulting in death.
Mechanistically, C5a regulated the IL-17A/IL-23 axis
in a 2-step process. C5a induced the release of IL-10 via
the PI3K-Akt and MEK1/2-ERK1/2 pathways. Such
pathways have been demonstrated earlier to be en-
gaged in C5a effects on signaling (36, 37). Subse-
quently, IL-10 potently acted in an autocrine or para-
crine fashion to antagonize IL-17A and IL-23. These
data expand previous reports that C5a can regulate
mediator production, such as IL-12 in human and
mouse macrophages (36, 38). Furthermore, we have
recently reported that C5a enhances release of the
isoform IL-17F (28), which has a 10- to 30-fold lower
bioactivity as compared to IL-17A, in terms of down-
stream gene activation, e.g., of CXCL1 (39). Therefore,
C5a appears to down-modulate the more potent IL-17A
while up-regulating the weaker IL-17F, perhaps shifting
the balance of IL-17A and IL-17F toward less biological
activity of the IL-17A/IL-17F system.
One major function of the complement system is
protection and clearance of pathogens in extracellular
compartments. By analogy, the immune functions of
IL-17A are also associated mainly with defense against
extracellular bacteria and fungi. Humans with a defect
that nullifies the ability to mount Th17 responses and
have reduced levels of IL-17A have recurrent C. albicans
and S. aureus infections in the skin and lungs (40).
Accordingly, this implies a somewhat redundant role
for the complement system and IL-17A. On the other
hand, there is abundant evidence demonstrating the
detrimental role of IL-17A in the pathogenesis of
autoimmune diseases, implying that the release of
IL-17A must be tightly controlled in order to provide
clearance of infectious pathogens without causing self-
Figure 7. C5a induces IL-10 by activation of PI3K-Akt and
MEK1/2-ERK1/2 signaling pathways. A) Flow cytometry de-
tection of phosphorylation of Akt at amino acid position
threonine 308 10 min after stimulation of Wt macrophages
with recombinant mouse C5a. B) Phosphorylation of
ERK1/2 at threonine 202 and tyrosine 204 in macrophages,
detected by flow cytometry after 10 min incubation with C5a.
C) Flow cytometry detection of phosphorylated Akt in F4/
80 macrophages from C57BL/6J or C5aR/ mice. Macro-
phages were incubated with LPS or LPS plus C5a for 20 min
or left untreated (Ctrl). D) Detection of phosphorylated
ERK1/2 in F4/80 macrophages from Wt or C5aR/ mice. Macrophages were incubated with LPS or LPS plus C5a for
20 min. E) Inhibition of IL-10 release from macrophages by specific blockade of the PI3K-Akt (LY294002, 100 M) and
MEK1/2 (PD98059, 50 M) pathways, 10 h. F) Suppression of IL-10 production by the MEK1/2 inhibitor U0126, 10 h.
Concentrations for LPS were 1 g/ml and for C5a 100 nM in all experiments. Error bars represent means 
 se. **P  0.01;
Student’s t test.
1649C5a SUPPRESSION OF THE IL-17A/IL-23 AXIS
inflicted persistent tissue inflammation. Conversely, the
absence of the C5aR and C3aR has been associated with
a trend toward greater disease activity in experimental
autoimmune encephalomyelitis (41). However, other
reports have favored either an enhancing or negligible
influence of the complement system for the develop-
ment of autoimmune disease (42–44). It has been
reported that C5a can skew release of Th1 cytokine
release, such as IL-12; cause accentuation of Th2 re-
sponses; and promote T-cell expansion (36, 38, 45–47).
In addition to our findings that IL-17A-producing mac-
rophages are regulated via engagement of C5aR with
C5a, other reports have recently described a role of the
complement system and C5a in Th17 cell responses,
e.g., in a disease model of asthma (42, 48, 49). For
example, dendritic cells from C5aR/ mice promoted
the induction of Treg and Th17 cells after stimulation
with ovalbumin or a TLR2 agonist (50). However, the
influence of complement activation as an inhibitory or
stimulatory factor on Th17 cell development might
depend on the experimental model studied, as well as
the time course and the magnitude of C5a generation.
IL-17, like C5a, is a powerful enhancer of innate
immunity, provided IL-17 and C5a are present locally,
but not systemically. Once these powerful agents ap-
pear in the plasma, this sets the stage for an exuberant
and destructive systemic inflammatory response, as has
been described in the setting of polymicrobial sepsis in
rodents (11, 12, 25). Therefore, tight regulation of
both IL-17A and C5a is essential if effective regulation
of innate immune systems is to be achieved.
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